ClearID Breast Cancer Genomic Test is Now Reimbursable Under Most Health Insurance Plans

Cynvenio Biosystems Aims to Make Genomic Testing More Accessible for all Cancer Patients and Physicians

LOS ANGELES, September 16, 2014 – Cynvenio Biosystems, Inc. announced today that it will be accepting payment for its ClearID Breast Cancer test under most health insurance plans including Aetna, UnitedHealth Group, Cigna, Assurant, Blue Cross/Blue Shield, Humana, Kaiser Permanente and various Health Maintenance Organizations (HMO), with the exception of Medicaid.

The ClearID Breast Cancer blood test uses DNA sequencing to assess breast cancer patients in the context of targeted therapy and to dynamically measure their response to treatment at the molecular level. ClearID is useful for monitoring patients without incurring radiation exposure, and when tissue biopsy is too difficult or risky to obtain.

“Today marks a critical milestone for ClearID.  We continue to push the envelope in reducing out-of-pocket costs so that more patients and physicians can access this genomic test and benefit from improved therapy selection and more individualized treatment plans,” said André de Fusco, CEO of Cynvenio. “ClearID will now be accessible to many more patients and physicians seeking critical knowledge on approved cancer therapies, drugs in development and the active clinical trials that may help improve outcomes.”

Effective immediately Cynvenio will submit ClearID claims to payers, including Medicare, and work with physicians in any claims appeal process. Physicians may download requisition forms and order the ClearID test at www.cynvenio.com/order-clearid/.

About Cynvenio Biosystems, Inc.

Cynvenio is a molecular information technology company focused on individualizing cancer treatment by providing longitudinal insights into each patient via the genomic analysis of their cancer from a standard blood draw. Cynvenio’s LiquidBiopsy® and ClearID™ clinical assays for solid tumors are used as therapy finders to periodically assess patients’ individual mutations and match them with targeted cancer therapies and clinical trials. Both blood tests can be used to complement traditional tissue biopsy analysis, or as standalone tests to find therapies for patients in which tissue biopsy is deemed difficult or too risky to harvest.

Cynvenio is headquartered in Westlake Village, California (Los Angeles). For more information, visit http://www.cynvenio.com.

LiquidBiopsy® is a registered trademark of Cynvenio Biosystems, Inc.